CHI Sixth Annual Immuno-Oncology Summit Europe
Join Isogenica in London at the Annunal Immuno-Oncology Summit
The Isogenica team will be attending in person at CHI’s annual Immuno-Oncology conference, taking place on 23rd-25th May.
Isogenica’s CSO, Dr Bill Eldridge, will be presentating exciting new data about our next generation therapeutics and multi-specific plug-&-play platform.
Join Bill on Wednesday 25th May at 09:35am GMT online or in person.
Alternatively, you can engage with the rest of the Isogenica Team at our poster presentation.
If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.
Further Information
Isogenica has develops single domain VHH therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
Contact
Business Development team
T +44 1799 533 680
E bd@isogenica.com
